Home > News > Effects of N-acetyl-cysteine on endothelial function and inflammation in patients with type 2 diabetes mellitus
Cardiovascular Disease
Read Time: < 1 min

Effects of N-acetyl-cysteine on endothelial function and inflammation in patients with type 2 diabetes mellitus

Published Online: July 30th 2018 Heart International 2009;4(1):e7
Authors: Allen Jeremias, Geetha Soodini, Eli Gelfand, Yizhen Xu, Robert C. Stanton, Edward S. Horton, David J. Cohen
Quick Links:
Abstract
Article
Article Information
Abstract:
Overview

Endothelial dysfunction has been associated
with premature vascular disease. There is
increasing data that N-acetyl-cysteine (NAC)
may prevent or improve endothelial dysfunction.
The aim of this study was to assess the
effects of NAC on endothelial function in
patients with type 2 diabetes mellitus, a population
at high risk for endothelial dysfunction.
Twenty-four patients with diabetes mellitus
were assigned randomly to initial therapy with
either 900 mg NAC or placebo twice daily in a
double-blind, cross-over study design. Flowmediated
vasodilation (FMD) of the brachial
artery was assessed at baseline, after four
weeks of therapy, after a four-week wash-out period, and after another four weeks on the
opposite treatment. Plasma and red blood cell
glutathione levels and high-sensitivity C-reactive
protein (CRP) were measured at all four
visits. At baseline, FMD was moderately
impaired (3.7±2.9%). There was no significant
change in FMD after four weeks of NAC
therapy as compared to placebo (0.1±3.6% vs.
1.2±4.2%). Similarly, there was no significant
change in glutathione levels. However, median
CRP decreased from 2.35 to 2.14 mg/L during
NAC therapy (p=0.04), while it increased from
2.24 to 2.65 mg/L with placebo. No side effects
were noted during the treatment period. In
this double-blind, randomized cross-over
study, four weeks of oral NAC therapy failed to
improve endothelial dysfunction in patients
with diabetes mellitus. However, NAC therapy
decreased CRP levels, suggesting that this
compound may have some efficacy in reducing
systemic inflammation.

Keywords

Endothelial function, diabetes mellitus, randomized trial, N-acetyl-cysteine.

Article:
Article Information:
Correspondence

Allen Jeremias, Stony Brook University Medical Center Health Science Center, T16-080 Stony Brook, NY 11794, USA E-mail: allen.jeremias@stonybrook.edu

Received

2009-07-07

Further Resources

Share this Article
Related Content In Cardiovascular Disease
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72